Solution for Method Development and Analytical Quality by Design - LabSolutions MD

Significance of the Topic

The Analytical Quality by Design (AQbD) framework integrates risk-based strategies and statistical experimental design to develop robust, reliable analytical methods in fewer trials. This approach addresses the need for reproducible, high-confidence results in pharmaceutical and industrial quality-control laboratories, reducing method development time and human error while ensuring regulatory compliance.

Objectives and Study Overview

This whitepaper presents the workflow and key functions of the LabSolutions MD software for AQbD-driven method development. It demonstrates how experimental design accelerates the screening, optimization, and validation phases of chromatography method development for simultaneous analysis of small-molecule drugs.

Methodology and Instrumentation

LabSolutions MD orchestrates:

• Screening Phase: Full factorial design for initial selection of mobile phases (two aqueous, three organic) and six reversed-phase columns across 36 experiments.
• Optimization Phase: Reduced-run designs (Box–Behnken and Central Composite) to model critical parameters—organic percentage, gradient endpoint, and column temperature—using 13–15 runs instead of 27.
• Validation Phase: Sequential design for robustness assessment by shifting factors ±1% organic ratio and ±1 °C oven temperature.

Used Instrumentation:

• Nexera Series UHPLC systems with high-pressure mobile-phase switching and blending capabilities.
• Nexera UC combined LC/Supercritical Fluid Chromatography platform.
• Shim-pack Scepter reversed-phase columns (C18, C8, C4, Phenyl, PFPP, C18 AQ HQ).
• SPD-M40 photodiode array detector and LCMS-2050 single-quadrupole mass spectrometer.
• LabSolutions MD software suite with DoE, chromatogram simulation, design-space plotting, and database integration.

Main Results and Discussion

• Screening outputs were ranked using a composite evaluation score (number of peaks × sum of pairwise resolutions) and ANOVA to identify factors with significant impact (p ≤ 0.05).
• Optimization via design space visualization revealed regions satisfying criteria for minimum resolution, peak symmetry, and total run time. Overlaid response surfaces led to selection of 60% acetonitrile, 42 °C oven temperature, and 75% gradient endpoint.
• Chromatogram simulation at untested design points validated model predictions without additional runs.
• Robustness tests confirmed negligible variation in separation across small deviations and different column lots.
• Automated peak tracking (i-PeakTracer) using UV and MS data streamlined compound identification across varied retention times.

Benefits and Practical Applications

• Significant reduction in experimental runs and operator workload through automated schedule generation and mobile-phase blending.
• Enhanced method reliability across instruments, operators, and column lots, supporting regulatory expectations for method robustness.
• Centralized database ensures data integrity and traceability from method planning through validation.
• Applicable to diverse chromatographic applications, including small molecules, oligonucleotides, monoclonal antibodies, and impurity profiling.

Future Trends and Potential Applications

• Integration of machine learning to predict optimal conditions from historical data.
• Expanded support for emerging separation modes such as hydrophilic interaction chromatography (HILIC) and capillary electrophoresis.
• Real-time in-silico chromatogram prediction and cloud-based collaborative design-space sharing.
• Enhanced MS coupling for high-throughput impurity identification in regulated environments.

Conclusion

LabSolutions MD exemplifies a comprehensive AQbD platform that leverages experimental design, statistical modeling, and automation to streamline chromatographic method development. By reducing trial numbers, improving robustness, and ensuring data integrity, it enables analysts to deliver reliable methods more efficiently and consistently.

References

1. Shimadzu Corporation. Efficient Method Development Based on Analytical Quality by Design with LabSolutions MD Software (C190-E284).
2. Shimadzu Corporation. Efficient Method Development of Oligonucleotides by Reversed-Phase Ion-Pair Chromatography.
3. Shimadzu Corporation. Efficient Method Development of Monoclonal Antibody Size Variants by Size Exclusion Chromatography.